Propentofylline: A nucleoside transport inhibitor with neuroprotective effects in cerebral ischemia
Identifieur interne : 004154 ( Main/Exploration ); précédent : 004153; suivant : 004155Propentofylline: A nucleoside transport inhibitor with neuroprotective effects in cerebral ischemia
Auteurs : Fiona E. Parkinson [Canada] ; Karl A. Rudolphi [Allemagne] ; Bertil B. Fredholm [Suède]Source :
- General Pharmacology [ 0306-3623 ] ; 1994.
English descriptors
- KwdEn :
- Adenosine (metabolism), Adenosine (physiology), Animals, Biological Transport (drug effects), Brain Ischemia (drug therapy), Cells, Cultured, Cerebrovascular Circulation (drug effects), Depression, Chemical, Excitatory Amino Acid Antagonists, Gerbillinae, Humans, Receptors, Purinergic P1 (drug effects), Xanthines (pharmacology), Xanthines (therapeutic use).
- MESH :
- chemical , drug effects : Receptors, Purinergic P1.
- chemical , metabolism : Adenosine.
- chemical , pharmacology : Xanthines.
- chemical , physiology : Adenosine.
- drug effects : Biological Transport, Cerebrovascular Circulation.
- drug therapy : Brain Ischemia.
- chemical , therapeutic use : Xanthines.
- Animals, Cells, Cultured, Depression, Chemical, Excitatory Amino Acid Antagonists, Gerbillinae, Humans.
Abstract
1. Adenosine is an endogenous neuroprotective agent; stimulation of A1 receptors decreases excitatory amino acid neurotransmission and stimulation of A2 receptors inhibits platelet and neutrophil activation and promotes vasodilation.2. Post-ischemic administration of propentofylline (HWA 285) reduces neuronal damage in gerbils and improves glucose metabolism in all regions of brain in acute stroke patients.3. Propentofylline inhibits the transport of adenosine into cultured cells and increases extracellular adenosine concentrations in ischemic brain. Thus, enhanced stimulation of adenosine receptors may account for some of the neuroprotective effects of this compound.4. Propentofylline inhibits free radical production by cultivated microglia cells, stimulates nerve growth factor production and inhibits cAMP-phosphodiesterase activity. These effects may also be important for neuroprotection.
Url:
DOI: 10.1016/0306-3623(94)90119-8
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000942
- to stream Istex, to step Curation: 000942
- to stream Istex, to step Checkpoint: 001A80
- to stream Main, to step Merge: 004910
- to stream PubMed, to step Corpus: 001947
- to stream PubMed, to step Curation: 001947
- to stream PubMed, to step Checkpoint: 001947
- to stream Ncbi, to step Merge: 002421
- to stream Ncbi, to step Curation: 002421
- to stream Ncbi, to step Checkpoint: 002421
- to stream Main, to step Merge: 004851
- to stream Main, to step Curation: 004154
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Propentofylline: A nucleoside transport inhibitor with neuroprotective effects in cerebral ischemia</title><author><name sortKey="Parkinson, Fiona E" sort="Parkinson, Fiona E" uniqKey="Parkinson F" first="Fiona E." last="Parkinson">Fiona E. Parkinson</name></author><author><name sortKey="Rudolphi, Karl A" sort="Rudolphi, Karl A" uniqKey="Rudolphi K" first="Karl A." last="Rudolphi">Karl A. Rudolphi</name></author><author><name sortKey="Fredholm, Bertil B" sort="Fredholm, Bertil B" uniqKey="Fredholm B" first="Bertil B." last="Fredholm">Bertil B. Fredholm</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7AC3112AFB310FD94F9CE5F76364F128F40C9C68</idno><date when="1994" year="1994">1994</date><idno type="doi">10.1016/0306-3623(94)90119-8</idno><idno type="url">https://api-v5.istex.fr/document/7AC3112AFB310FD94F9CE5F76364F128F40C9C68/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000942</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000942</idno><idno type="wicri:Area/Istex/Curation">000942</idno><idno type="wicri:Area/Istex/Checkpoint">001A80</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001A80</idno><idno type="wicri:doubleKey">0306-3623:1994:Parkinson F:propentofylline:a:nucleoside</idno><idno type="wicri:Area/Main/Merge">004910</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:7875526</idno><idno type="wicri:Area/PubMed/Corpus">001947</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001947</idno><idno type="wicri:Area/PubMed/Curation">001947</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001947</idno><idno type="wicri:Area/PubMed/Checkpoint">001947</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001947</idno><idno type="wicri:Area/Ncbi/Merge">002421</idno><idno type="wicri:Area/Ncbi/Curation">002421</idno><idno type="wicri:Area/Ncbi/Checkpoint">002421</idno><idno type="wicri:doubleKey">0306-3623:1994:Parkinson F:propentofylline:a:nucleoside</idno><idno type="wicri:Area/Main/Merge">004851</idno><idno type="wicri:Area/Main/Curation">004154</idno><idno type="wicri:Area/Main/Exploration">004154</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Propentofylline: A nucleoside transport inhibitor with neuroprotective effects in cerebral ischemia</title><author><name sortKey="Parkinson, Fiona E" sort="Parkinson, Fiona E" uniqKey="Parkinson F" first="Fiona E." last="Parkinson">Fiona E. Parkinson</name><affiliation wicri:level="4"><country>Canada</country><wicri:regionArea>Department of Pharmacology and Therapeutics, Faculty of Medicine University of Manitoba, Winnipeg, Manitoba</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation></author><author><name sortKey="Rudolphi, Karl A" sort="Rudolphi, Karl A" uniqKey="Rudolphi K" first="Karl A." last="Rudolphi">Karl A. Rudolphi</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Hoechst AG</wicri:regionArea></affiliation></author><author><name sortKey="Fredholm, Bertil B" sort="Fredholm, Bertil B" uniqKey="Fredholm B" first="Bertil B." last="Fredholm">Bertil B. Fredholm</name><affiliation wicri:level="1"><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Physiology and Pharmacology, Karolinska Institutet S-171 77 Stockholm</wicri:regionArea><wicri:noRegion>Karolinska Institutet S-171 77 Stockholm</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">General Pharmacology</title><title level="j" type="abbrev">GPH</title><idno type="ISSN">0306-3623</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1994">1994</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="1053">1053</biblScope><biblScope unit="page" to="1058">1058</biblScope></imprint><idno type="ISSN">0306-3623</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0306-3623</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine (metabolism)</term><term>Adenosine (physiology)</term><term>Animals</term><term>Biological Transport (drug effects)</term><term>Brain Ischemia (drug therapy)</term><term>Cells, Cultured</term><term>Cerebrovascular Circulation (drug effects)</term><term>Depression, Chemical</term><term>Excitatory Amino Acid Antagonists</term><term>Gerbillinae</term><term>Humans</term><term>Receptors, Purinergic P1 (drug effects)</term><term>Xanthines (pharmacology)</term><term>Xanthines (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Purinergic P1</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Adenosine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Xanthines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Adenosine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Biological Transport</term><term>Cerebrovascular Circulation</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Brain Ischemia</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Xanthines</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cells, Cultured</term><term>Depression, Chemical</term><term>Excitatory Amino Acid Antagonists</term><term>Gerbillinae</term><term>Humans</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">1. Adenosine is an endogenous neuroprotective agent; stimulation of A1 receptors decreases excitatory amino acid neurotransmission and stimulation of A2 receptors inhibits platelet and neutrophil activation and promotes vasodilation.2. Post-ischemic administration of propentofylline (HWA 285) reduces neuronal damage in gerbils and improves glucose metabolism in all regions of brain in acute stroke patients.3. Propentofylline inhibits the transport of adenosine into cultured cells and increases extracellular adenosine concentrations in ischemic brain. Thus, enhanced stimulation of adenosine receptors may account for some of the neuroprotective effects of this compound.4. Propentofylline inhibits free radical production by cultivated microglia cells, stimulates nerve growth factor production and inhibits cAMP-phosphodiesterase activity. These effects may also be important for neuroprotection.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Canada</li><li>Suède</li></country><region><li>Manitoba</li></region><settlement><li>Winnipeg</li></settlement><orgName><li>Université du Manitoba</li></orgName></list><tree><country name="Canada"><region name="Manitoba"><name sortKey="Parkinson, Fiona E" sort="Parkinson, Fiona E" uniqKey="Parkinson F" first="Fiona E." last="Parkinson">Fiona E. Parkinson</name></region></country><country name="Allemagne"><noRegion><name sortKey="Rudolphi, Karl A" sort="Rudolphi, Karl A" uniqKey="Rudolphi K" first="Karl A." last="Rudolphi">Karl A. Rudolphi</name></noRegion></country><country name="Suède"><noRegion><name sortKey="Fredholm, Bertil B" sort="Fredholm, Bertil B" uniqKey="Fredholm B" first="Bertil B." last="Fredholm">Bertil B. Fredholm</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004154 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004154 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:7AC3112AFB310FD94F9CE5F76364F128F40C9C68
|texte= Propentofylline: A nucleoside transport inhibitor with neuroprotective effects in cerebral ischemia
}}
| This area was generated with Dilib version V0.6.29. |  |